HCWBHCW Biologics Inc
$3.28
$0.098
(2.90%)
Pre-Market
Reported EarningsMay 14
Mkt Cap$6.12M
Vol7,097.00
HCW Biologics Commences 1-for-6 Reverse Stock Split
(RTTNews) - HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, Friday announced that it has been approved for a 1-for-6 reverse stock split of the company's common stock, with par value of $0.0001, effective June 30...
Nasdaq News: Markets
Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss
HCW Biologics reports positive Phase 1 data for HCW9302, with all 2nd-cohort alopecia patients showing a clinical response.read more...
Benzinga
Why Is HCW Biologics Stock Surging On Friday?
HCW Biologics Inc. (NASDAQ: HCWB) stock rallies on Friday as a $4 million private placement offering boosts liquidity for its clinical trials.read more...
Benzinga
This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners
The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS
24-7 Market News
Why HCW Biologics Stock Is Surging On Thursday?
HCW Biologics Inc. (NASDAQ:HCWB) stock is rallying after securing a $4 million private placement to fund its clinical pipeline. Read the full market breakdown.read more...
Benzinga
Biotech and Biologics Break Out: These Tiny Stocks Are Suddenly Dominating the Market Conversation
Emerging biotech and biologics names exploded onto traders’ radar Wednesday as a wave of clinical milestones, regulatory momentum, strategic acquisitions, and high-volume technical breakouts fueled aggressive speculation across the sector. $HCWB, $TGNT, $KBLB, $SLS, $RKDA, $ROIV, $SLXN
24-7 Market News
Why HCW Biologics Stock Is Falling On Tuesday?
HCW Biologics Inc. (NASDAQ: HCWB) stock falls on Tuesday. Retail traders lock in gains after a 262% surge driven by Q1 earnings and pipeline updates.read more...
Benzinga
What's Going On With HCW Biologics Stock Monday?
HCW Biologics (HCWB) reports Q1 EPS of $0.37 and $6.54M in sales. Find out why the stock skyrocketed and what's next.read more...
Benzinga
Clinical-Stage Biopharma Surges on Profit Swing and Imminent Phase 1 Data Readout
The market for autoimmune disease therapies is being reshaped by a new generation of biologics targeting regulatory T cells, the immune system's own braking mechanism. Alopecia areata, an autoimmune disorder that causes patchy or complete hair loss, affects millions worldwide and has only recently received its first FDA-approved oral therapies, each carrying significant tolerability concerns. Developers chasing safer, more selective alternatives have made Treg-expanding approaches one of the most closely watched corners of clinical-stage immunology.Shares of HCW Biologics Inc. (Nasdaq: ...
AllPennyStocks.com
Clinical-Stage Biopharma Surges on Profit Swing and Imminent Phase 1 Data Readout
The market for autoimmune disease therapies is being reshaped by a new generation of biologics targeting regulatory T cells, the immune system's own braking mechanism. Alopecia areata, an autoimmune disorder that causes patchy or complete hair loss, affects millions worldwide and has only recently received its first FDA-approved oral therapies, each carrying significant tolerability concerns. Developers chasing safer, more selective alternatives have made Treg-expanding approaches one of the most closely watched corners of clinical-stage immunology.Shares of HCW Biologics Inc. (Nasdaq: ...
AllPennyStocks.com
<
1
2
...
>
